Project Grant K22CA276360
Award Date
12/17/24
Completion Date
11/30/27
Dollars Obligated
$192K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $616,495.00 to The University of Texas M.D. Anderson Cancer Center to support research on the biological role of sulfatide in the development and progression of pancreatic cancer precursor lesions. The key objectives are to: Define the biological functions of sulfatide in pancreatic cancer precursor lesions, particularly intraductal papillary mucinous neoplasms (IPMNs), using...
The National Cancer Institute awarded a $342,397 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Wayne State University to investigate the relationship between MAIT cells and the microbiome in pancreatic cancer liver metastasis. The project aims to advance understanding of this connection and its potential impact on pancreatic cancer progression. The award period runs from September 30, 2024 to April 28, 2028, and the research will be conducted at Wayne State University in Detroit,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research program) provides $537,985 to the University of Texas MD Anderson Cancer Center to deeply characterize the location, distribution, and spatial functionality of microbes within the tumor microenvironment of primary pancreatic ductal adenocarcinoma (PDAC) tumors, as well as their influence on tumor growth, pre-metastatic niche formation, and liver metastasis. The research will utilize...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
The National Cancer Institute awarded a Project Grant under the Cancer Biology Research (CFDA 93.396) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The $654,197 grant, awarded on April 8, 2025, supports research to define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies, elucidate the contribution of stromal subtypes to chemoresistance, and identify extracellular vesicle...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $754,766.00 to The University of Texas M.D. Anderson Cancer Center to investigate the role of microbiota and microbial extracellular vesicles in metastatic dormancy in melanoma. The award period runs from November 1, 2024 to October 31, 2027. The University of Texas M.D. Anderson Cancer Center is a prominent academic medical center with extensive...
The National Cancer Institute (NCI) awarded a $110,550 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The funding supports research aimed at understanding the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. Specifically, the project investigates the role of regulatory T cells in suppressing anti-tumor immune responses in...
The National Institutes of Health's National Cancer Institute awarded a $283,136 Project Grant to the Regents of the University of Michigan under the Cancer Research Manpower federal grant program (CFDA 93.398). The award will support research investigating cellular communication in the tumor microenvironment of pancreatic cancer. The grantee will examine how hedgehog signaling alters the immune landscape and endothelial cell function through fibroblast interactions. They will also determine the...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The University of Texas MD Anderson Cancer Center in the amount of $139,247 with a period of performance from June 1, 2025 to May 31, 2030. The purpose of this grant is to conduct research on harnessing extrachromosomal DNA (ecdna) detection in antigen-presenting cells to enhance anti-tumor immunity. The key objectives are to: 1) Mechanistically examine how ecdna detection in...